218 results about "Phosphatine" patented technology

Disclosed herein are crystalline forms of phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα) inhibitors, and formulations and uses of same.

The invention belongs to the technical field of RNA biological prevention and treatment, and particularly relates to dsRNA for preventing and treating crop anthracnose and application of the dsRNA. The dsRNA is targeted inositol phosphatidylceramide (IPC) synthetase coding gene dsRNA, and is obtained by transcription of a part of sequence (SEQ ID No.1) of an inositol phosphatidylceramide (IPC) synthetase coding gene CaAUR1, the gene segment is a segment of a target gene for preventing and treating crop anthracnose, and the dsRNA obtained by transcription can obviously reduce pathogenicity of mango anthracnose bacteria, and has the effects of keeping mango fresh, preventing and treating anthracnose. And the compound can be used for preventing and treating the crop anthracnose or preparing products for preventing and treating the crop anthracnose.

The invention provides a method for preparing high-purity phosphatidylserine by a batch enzyme catalysis method based on dynamic choline removal, and belongs to the technical field of enzymatic reaction. According to the method disclosed by the invention, in a reaction system for preparing phosphatidylserine, a byproduct choline is selectively adsorbed by adopting resin. Choline in a reaction system is removed in real time through the integrated adsorption separation module, the enzyme inhibition problem is solved, and meanwhile, the PC conversion rate is larger than or equal to 98% and the PS purity is larger than or equal to 96% in combination with the immobilized enzyme circulation technology; the enzyme can be reused for more than or equal to 20 times (activity retention is more than or equal to 90%); and the choline residual concentration is less than or equal to 0.5 mM (an inhibition threshold value or less).

Methods for treating cancers and precancerous conditions by administering an effective amount of a radiolabeled agent that targets cell surface phosphatidylserine, alone or in combination with other therapies, are provided. The radiolabeled phosphatidylserine targeting agent delivers radiation to cells that externally present phosphatidylserine, such as tumor cells, depleting those cells and neighboring malignant cells to effect overall tumor reduction. Radiation delivered by the radiolabeled phosphatidylserine targeting agent itself increases the cell surface expression of phosphatidylserine, leading to a feed-forward mechanism that drives further accumulation of the phosphatidylserine targeting agent at target lesions to enhance its therapeutic effect.

The invention provides a metabolic marker combination for ovarian cancer diagnosis and application thereof, and belongs to the technical field of in-vitro diagnosis. The invention provides a metabolic marker combination for ovarian cancer diagnosis. The metabolic marker combination comprises phosphatidylcholine 34: 4, threonic acid, phosphatidylcholine 32: 2, pyroglutamic acid, phosphatidylcholine 36: 6 and ceramide d38: 2. According to the metabolic marker combination, plasma samples of a healthy subject and an ovarian cancer patient are analyzed, a group of biomarkers with significant difference are screened from the plasma samples, and the metabolic marker combination is a non-invasive, non-invasive and high-accuracy metabolic marker combination for distinguishing the healthy subject and the ovarian cancer patient. The method can be used for constructing a diagnostic model for distinguishing healthy subjects from ovarian cancer patients. The metabolic marker combination disclosed by the invention can be used for improving the diagnosis and evaluation capability of ovarian cancer patients, so that early discovery, early diagnosis and early intervention can be realized clinically, and the survival rate of the ovarian cancer patients is improved.

Conjugates comprising a fibroblast activation protein α (FAP-α)-targeted ligand, a bifunctional or trifunctional linker, and a phosphatidylinositol-3-kinase (PI3k) inhibitor; uses of the conjugates in the manufacture of a medicament for inhibiting progression of fibrosis in a subject; and a method of use in inhibiting progression of fibrosis in a subject.

The invention discloses a metabolic marker composition for early diagnosis of cervical cancer as well as a screening method and application of the metabolic marker composition. The metabolic marker composition for early diagnosis of cervical cancer comprises pyroglutamic acid, lysophosphatidylcholine 20: 3, phosphatidylcholine 32: 2 and pyruvic acid. The metabolic marker composition provided by the invention has relatively high sensitivity and specificity when being used for early-stage cervical cancer diagnosis, can realize accurate screening of early-stage cervical cancer, and provides important help for prevention of cervical cancer and reduction of morbidity. Meanwhile, when the metabolic marker composition is used for early-stage cervical cancer diagnosis, operation is easy, a sample is convenient to obtain, cost is low, invasion is avoided, a patient can receive detection more conveniently, rapidly and safely, and the metabolic marker composition is more suitable for large-scale population screening and regular tracking in areas with shortage of medical resources.

The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer and application thereof, and belongs to the field of markers for detecting ovarian cancer. The invention discloses a specific metabolic marker combination for diagnosing ovarian cancer. The specific metabolic marker combination comprises phosphatidylcholine 36: 6, sphingomyelin d40: 2 and sphingomyelin d41: 2. According to the invention, a metabonomics technology is used to screen out a specific metabolism marker combination for diagnosing ovarian cancer, and the specific metabolism marker combination has high sensitivity in ovarian cancer diagnosis and has high diagnosis capability for ovarian cancer diagnosis. The specific metabolic marker combination also has high specificity in ovarian cancer diagnosis, but is not applicable to diagnosis of endometrial cancer and cervical cancer. In addition, the plasma sample acquisition mode has the advantages of non-invasiveness and convenience, and has a wide application prospect in the research of biomarkers.

This disclosure provides compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit phosphatidylinositol 4,5-bisphosphate 3 kinase (PI3K) isoform alpha (PI3Kα). These compounds are useful for treating a disease in which increased PI3Kα activation contributes to the pathology, symptoms, and / or progression of the disease (e.g., cancer) in a subject.

The invention relates to the technical field of cell apoptosis detection, in particular to a kit for cell apoptosis detection and a product thereof. The Annexin V-FITC provided by the invention can well realize the detection of apoptosis, has obvious linear correlation with the apoptosis rate, and can realize the high-sensitivity detection of the occurrence of apoptosis. The method and the kit for detecting cell apoptosis can effectively identify phosphatidylserine exposed on the outer surface of apoptotic cells, and have more detection advantages compared with Annexin V full length. The sensitivity and the cell apoptosis rate of the detection method have a good linear relationship, and the detection method has a relatively great application prospect.

The present invention relates to the technical field of vaccines and adjuvants, and specifically to the use of phosphatidylethanolamine as a metabolic adjuvant for respiratory syncytial virus (RSV) vaccines. Phosphatidylethanolamine, as a metabolic adjuvant for RSV vaccines, can modulate T cell immune responses, prevent the occurrence of VED, and generate balanced immune memory in vaccine recipients. When infected with RSV, it provides protection while preventing the occurrence of vaccine-enhanced inflammatory diseases, achieving both safety and effectiveness.

Disclosed herein are crystalline forms of phosphatidylinositol 4,5-bisphosphate 3-kinase (PI3K) isoform alpha (PI3Kα) inhibitors, and formulations and uses of same.

The invention provides a nutritional composition capable of influencing protein expression of brain hippocampus and application of the nutritional composition. The nutritional composition of the present invention comprises sialic acid, sphingomyelin and phosphatidylcholine, in which the ratio of the sum of the contents of sphingomyelin and phosphatidylcholine to the content of sialic acid is 1: 1 by weight, and the ratio of sphingomyelin to phosphatidylcholine is 0.2: 1 to 1.4: 1 based on the total weight of sphingomyelin and phosphatidylcholine. The composition can increase the gray matter volume of the brain and can improve the expression of BDNFmRNA of the hippocampus and the prefrontal cortex.

The invention provides a blood marker for distinguishing lung cancer and non-lung cancer diseases and application of the blood marker, and belongs to the technical field of biomarkers. The blood marker for distinguishing lung cancer and non-lung cancer diseases comprises at least five metabolites as follows: phosphatidylethanolamine (36: 4), lysophosphatidylcholine 18: 1e, phosphatidylethanolamine 38: 7e, sphingomyelin d38: 5, dodecanedioic acid, N-acetylputrescine, L-glutamyl-L-glutamine, hippuric acid, trans-cyclohexane-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3, 4-triazole-1, 3-triazole-1, 3, 4- The compound is prepared from 1, 2-dicarboxylic acid, glycochenodeoxycholic acid, allantoic acid, L-valine, methyleucine and 4-guanidinobutyric acid. A diagnosis model is constructed based on the blood marker, and the area under curve (AUC) is greater than 0.77, which indicates that the diagnosis result is accurate and reliable. The invention provides an effective marker for diagnosis of lung cancer and differential diagnosis of lung cancer and non-lung cancer diseases, greatly simplifies experimental operation, and has important clinical diagnosis significance.

The present composition comprises magnesium-L-threonate and a neurotransmitter such as, but not limited to phosphatidylserine and optionally, at least one of vitamin C, vitamin B6, and vitamin D3. The composition has been shown to increase at least one of memory or cognition in clinical study subjects. The present disclosure is further directed to methods of identifying and a subject with a memory or cognitive deficiency and administering a therapeutically effective amount of a formula comprising magnesium-L-threonate and a neurotransmitter to improve the memory and / or cognitive deficiency. In some implementations, the magnesium-L-threonate is Magtein®. It is also intended that any other neurotransmitter that results in a synergistic composition of the magnesium-L-threonate and the neurotransmitter by administered to improve a subject's memory and / or cognition.

The invention discloses a compound grease feed additive for improving breeding quality of channa maculata and application. The method comprises the following steps: (1) preparing experimental feed; the method comprises the following steps: respectively preparing an experimental group ARA 1.5 added with 1.5% of arachidonic acid and an experimental group ARA + PC added with 1.5% of arachidonic acid and 1.5% of phosphatidylcholine; (2) feeding; (3) after the culture experiment is finished, treating and detecting the channa maculata; (4) carrying out an artificial propagation test; (5) carrying out ovarian steroid synthesis related gene expression detection; and (6) carrying out data statistical analysis. By adding arachidonic acid (ARA) and phosphatidylcholine (PC) into the feed, the breeding performance of channa maculata and the quality of fry are improved, and the feed has very important significance for improving the aquatic product efficiency of high-quality fry of channa maculata in aquaculture.

The invention relates to a health-care food composition as well as a preparation method and application thereof. The invention provides a composition with a memory improving function, the composition comprises, by weight, 1-10 parts of cistanche, 2-15 parts of spina date seed, 2-15 parts of poria cocos, 2-30 parts of Chinese yam, 1-12 parts of wolfberry, 1-10 parts of fructus alpiniae oxyphyllae, 1-9 parts of ginseng, 0.1-0.7 part of walnut peptide, and 0.1-0.6 part of phosphatidylserine, and the composition provided by the invention has the efficacy of tonifying kidney, strengthening brain, nourishing blood and tranquilizing.

Disclosed in the present invention is a phosphatidylserine and docosahexaenoic acid (DHA) composite, and its application thereof in a functional preparation, belonging to the field of health-care food. By combining two substances in a specific ratio and further applying them to edible functional preparations, brain entry efficiency of unsaturated fatty acids including DHA is improved. The ratio verifies a synergistic interaction mechanism of two active ingredients. Phosphatidylserine promotes enrichment of fatty acids such as the DHA in a brain by enhancing permeability of a blood-brain barrier, promotes neurogenesis, and enhances learning and memory abilities. Moreover, combination of the phosphatidylserine (PS) and the DHA can significantly improve an expression level of neurotrophic factors and protect and repaire a nervous system. (Figl)

The present disclosure concerns methods for treating pancreatic cancer cells with a combination of gemcitabine (GEM) and SapC-DOPS. In some aspects, GEM treatment preferentially targets G1 phase cells which are low in surface phosphatidylserine (PS), resulting in an increased median surface PS level of PDAC cells. Inversely, SapC-DOPS targets high surface PS cells which are predominantly in the G2 / M phase. In other aspects, a combination therapy on tumors in vivo with SapC-DOPS and GEM or Abraxane® (Abr) / GEM is demonstrated to significantly inhibit tumor growth and increases survival.

The invention discloses a biomarker for distinguishing prostatic cancer and benign prostatic hyperplasia and application thereof, and particularly provides phosphatidyl ethanolamine (20: 0 / 15: 0) as a biomarker for screening prostatic cancer, the phosphatidyl ethanolamine (20: 0 / 15: 0) has higher specificity and better diagnostic efficiency than TPSA, can reduce unnecessary prostatic biopsy puncture, and can be used for screening prostatic cancer. The pain of a patient is relieved, and missed diagnosis of conventional puncture is reduced.

A reagent for measuring activated partial thromboplastin time, the reagent comprising phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidylethanolamine (PE), wherein the ratio (PS / PC) of the concentration of the PS to the concentration of the PC is 0.26-2.00, and the concentration of the PS is 14-60 µg / mL.

This invention belongs to the fields of pharmaceutical biotechnology and clinical medicine, specifically relating to a peripheral blood phosphatidylethanolamine biomarker for the objective diagnosis of depression, and particularly to the application of phosphatidylethanolamine (PE) (18:1 / 18:3) in the diagnosis and risk assessment of depression. This invention provides an objective diagnostic method based on peripheral blood, overcoming the inherent subjectivity of traditional psychiatric diagnoses, and can be used for the auxiliary diagnosis, early screening, and risk assessment of depression.

The invention discloses application of phosphatidylserine-hydrocortisone microvesicles in preparation of a medicine for treating microvascular regeneration after cerebral apoplexy, and relates to the technical field of biomedicine. According to the microbubble, the blood brain barrier can be accurately opened through the ultrasonic vacuolation technology, the medicine can be delivered in a targeted mode, nerve protection and function improvement are accurately evaluated through ultrasonic super-resolution micro blood flow imaging, and microvessel regeneration is accurately regulated and controlled based on H3K18 lactic acid modification.

The application belongs to the technical field of molecular biology, and particularly relates to metabolic markers for evaluating the prognosis of patients with hypertrophic cardiomyopathy and application thereof. The application determines that one or more of 3-hydroxyrilotene, asparagine-lysine, cyclohexylamine, arachidonic acid, aconitic acid, propionyl carnitine, ceramide, tryptophan, 3-hydroxysebacic acid, traumatic acid, phosphatidylcholine, alanine-proline, lysophosphatidylcholine, taurine and S-garlicin cysteine are related to the prognosis of hypertrophic cardiomyopathy, can evaluate the prognosis of patients with hypertrophic cardiomyopathy after undergoing muscle resection of interventricular septum, and shows accurate judgment on all-cause death or rehospitalization, cardiovascular events and postoperative new-onset arrhythmia. Finally, all the prognostic biomarkers are reproduced in an independent cohort, which is helpful for postoperative risk evaluation of patients with hypertrophic cardiomyopathy, has high specificity and high sensitivity.

This invention provides the application of phosphatidylinositol (16:0 / 18:3(9 cis, 12 cis, 15 cis)) in the identification of Hainan camellia, relating to the field of food testing technology. The phosphatidylinositol (16:0 / 18:3(9 cis, 12 cis, 15 cis)) can be used as a characteristic marker for the identification of Hainan camellia. This invention is the first to discover that the kernels of Hainan camellia contain high levels of phosphatidylinositol (16:0 / 18:3(9 cis, 12 cis, 15 cis)), while phosphatidylinositol (16:0 / 18:3(9 cis, 12 cis, 15 cis)) is not found or present in extremely low amounts in the kernels of other camellia species besides Hainan camellia. Phosphatidylinositol (16:0 / 18:3(9 cis, 12 cis, 15 cis)) can be used to identify and distinguish Hainan camellia from other camellia species. Furthermore, this identification method is simple to operate and achieves rapid, objective, and accurate identification of Hainan camellia.

The application relates to application of phosphatidylinositol and phosphatidylglycerol as metabolic markers for predicting intracranial atherosclerosis progression, and belongs to the technical field of medical biological detection. In the scheme, single-sample MR analysis is carried out by combining RICAS cohort data with external database data, causal correlation between metabolites and ICAS is analyzed, and serum biomarkers phosphatidylinositol PI 18:0 / 22:6 and phosphatidylglycerol PG 18:1 / 18:2 for ICAS occurrence and development are screened out by combining characteristic metabolic changes of ICAS with causal correlation analysis. ICAS progression is collected through prospective follow-up of the RICAS cohort, the correlation between the serum biomarkers and the ICAS progression is established, and it is verified that the serum biomarkers have transformation application value and can be used as a new biomarker for early prediction of ICAS progression and derivation.

A pharmaceutical combination comprising (i) a phosphatidylserine (PS) blocker, (ii) an immune stimulant, and (iii) one or more chemotherapeutic agents; compositions and sustained-release formulations comprising the same; and their use in cancer immunotherapy; and a method of preparing a sustained-release formulation.

This invention relates to the prevention and / or treatment of protein tyrosine kinase-mediated diseases, particularly phosphatidylinositol 3-kinase (PI3Ks)-mediated diseases. PI3Ks are well known as oncological targets, and several PI3K inhibitors have been developed that inhibit numerous class 1A PI3K isoforms. The development of selective inhibitors of PI3K-α may enable sufficient targeted inhibition while avoiding some of the known toxic drawbacks of pan-PI3K inhibitors. The inventors have discovered that a novel carbamoti-oil-pyrrolidine-carboxamide compound of formula (I) exhibits advantageous PI3K inhibitory activity, particularly with high selectivity for the isoform PI3K-α. In particular, this invention relates to the compound of formula (I), or deuterated or tritiated forms of the compound of formula (I), and pharmaceutically acceptable salts thereof. [Formula 1] The present invention also relates to pharmaceutical compositions containing a compound of formula (I) for use in the treatment and / or prevention of protein tyrosine kinase-mediated diseases, and to a compound of formula (I).

The present application belongs to the technical field of pharmaceutical compositions, and particularly relates to a composition with sleep improvement effect and application thereof.The composition comprises gamma-aminobutyric acid, Poria cocos extract, and can further comprise Rhizoma Polygonati extract and phosphatidylserine.The composition can achieve the effect of sleep improvement within a specific ratio range.The composition takes into account functionality and nutrition, and exhibits broad application prospects in the aspect of sleep improvement function.

The application belongs to the technical field of biology and particularly relates to application of phosphatidylglycerol. The phosphatidylglycerol PG (20:4_22:6) is used as a biomarker, and through analysis on metabolites of follicular fluid, the application realizes diagnosis of decreased ovarian reserve (DOR) with high sensitivity, high specificity and high accuracy.